-
Je něco špatně v tomto záznamu ?
DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment
Z. Pavelek, M. Novotný, B. Klímová, M. Peterka, P. Potužník, M. Kövári, M. Vališ
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze IV, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
- MeSH
- autoaplikace MeSH
- interferon beta 1a terapeutické užití MeSH
- lidé MeSH
- postižení * MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie MeSH
- roztroušená skleróza * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze IV MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
PURPOSE: The aim of this article is to provide unique and detailed data on how patients rate the RebiSmart 2.0 in the specific User Study Questionnaire (USQ) domains, and the relationship between their rating and individual level of disability, baseline demographic/socioeconomic factors, and adherence. PATIENTS AND METHODS: Twelve-month, phase IV, observational, multicenter study (no placebo or comparator) to evaluate the ease of use of the RebiSmart autoinjector for self-injection during treatment of CIS/RRMS subjects with Rebif 44 mcg sc three times a week by USQ. A total of 290 subjects participated in the study, with 249 (85.86%) completing the entire study period. RESULTS: The endpoint results demonstrated a very high proportion (>95%) of patients with a positive evaluation of the overall convenience of RebiSmart at each study visit. At the end of the study, all patients would recommend the device to others who need Rebif therapy. The proportion of patients rating the RebiSmart ease of use by individual domains (self-injection steps, changing the cartridge, using the device away from home) as "very easy to use" or "easy to use" and the proportion of patients rating the RebiSmart functions as "helpful" or "very helpful" were more than 80% for each domain at each study visit. CONCLUSION: These findings are in line with the potential benefits of RebiSmart to treatment adherence. They demonstrate an overall, very good perception of the device by patients and its individual functions.
Department of Neurology University Hospital Hradec Kralove Hradec Kralove Czech Republic
Department of Neurology University Hospital Plzen Plzen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004482
- 003
- CZ-PrNML
- 005
- 20220127145214.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/03007995.2021.1880886 $2 doi
- 035 __
- $a (PubMed)33538199
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pavelek, Zbyšek $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 245 10
- $a DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment / $c Z. Pavelek, M. Novotný, B. Klímová, M. Peterka, P. Potužník, M. Kövári, M. Vališ
- 520 9_
- $a PURPOSE: The aim of this article is to provide unique and detailed data on how patients rate the RebiSmart 2.0 in the specific User Study Questionnaire (USQ) domains, and the relationship between their rating and individual level of disability, baseline demographic/socioeconomic factors, and adherence. PATIENTS AND METHODS: Twelve-month, phase IV, observational, multicenter study (no placebo or comparator) to evaluate the ease of use of the RebiSmart autoinjector for self-injection during treatment of CIS/RRMS subjects with Rebif 44 mcg sc three times a week by USQ. A total of 290 subjects participated in the study, with 249 (85.86%) completing the entire study period. RESULTS: The endpoint results demonstrated a very high proportion (>95%) of patients with a positive evaluation of the overall convenience of RebiSmart at each study visit. At the end of the study, all patients would recommend the device to others who need Rebif therapy. The proportion of patients rating the RebiSmart ease of use by individual domains (self-injection steps, changing the cartridge, using the device away from home) as "very easy to use" or "easy to use" and the proportion of patients rating the RebiSmart functions as "helpful" or "very helpful" were more than 80% for each domain at each study visit. CONCLUSION: These findings are in line with the potential benefits of RebiSmart to treatment adherence. They demonstrate an overall, very good perception of the device by patients and its individual functions.
- 650 12
- $a postižení $7 D006233
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferon beta 1a $x terapeutické užití $7 D000068556
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a autoaplikace $7 D012646
- 655 _2
- $a klinické zkoušky, fáze IV $7 D017429
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Novotný, Michal $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Klímová, Blanka $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Peterka, Marek $u Department of Neurology, University Hospital Plzen, Plzen, Czech Republic
- 700 1_
- $a Potužník, Pavel $u Department of Neurology, University Hospital Plzen, Plzen, Czech Republic
- 700 1_
- $a Kövári, Martina $u Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Vališ, Martin $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 37, č. 4 (2021), s. 589-596
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33538199 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145210 $b ABA008
- 999 __
- $a ok $b bmc $g 1751827 $s 1155631
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 37 $c 4 $d 589-596 $e 20210213 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
- LZP __
- $a Pubmed-20220113